ALG-000184, Publications Monotherapy with the Capsid Assembly Modulator ALG-000184 Results in Rapid Viral Load Reduction and High Viral Suppression Rates in Untreated HBeAg-Negative Subjects with Chronic Hepatitis B Virus Infection
ALG-000184, Publications The Discovery and Preclinical Profile of ALG-000184, a Prodrug of the Potent Hepatitis B Virus Capsid Assembly Modulator ALG-001075
ALG-055009, Publications ALG-055009, a Novel Thyroid Hormone Receptor Beta (THR-β) Agonist, was Well-tolerated with Significant Reductions in Liver Fat at Week 12 in Non-cirrhotic MASH Patients in the Ongoing Randomized, Double-Blind, Placebo-controlled Phase 2
ALG-055009, Publications Nonclinical Toxicology Profile of ALG-055009, a Novel and Potent Thyroid Hormone Receptor β Agonist, for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)
ALG-000184, Publications Monotherapy with the Capsid Assembly Modulator, ALG-000184, Results in High Viral Suppression Rates in Untreated HBeAg+ and HBeAg- Subjects with Chronic Hepatitis B or Chronic Hepatitis B Virus Infection
ALG-000184, Publications Capsid Assembly Modulators Such as ALG-001075 Induce Profound HBV DNA Knockdown and Directly Target HBeAg In Vitro
Preclinical, Publications Discovery and Preclinical Characterization of ALG-093940, a Potent and Orally Bioavailable Small Molecule PD-L1 Inhibitor for the Treatment of Cancer
Preclinical, Publications Two Pre-clinical Short Interfering RNA (siRNA) Molecules Targeting Human HSD17β13 for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis
Preclinical, Publications Discovery and Optimization of the Pre-Clinical Efficacy of Human PNPLA3-Targeting Short Interfering RNA Molecules (siRNAs) for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis
Publication, Publications Discovery and Preclinical Profile of ALG-055009, a Potent and Selective Thyroid Hormone